Cellectar Biosciences, Inc. (CLRB) stock
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.92−0.09 (-8.88%)
Close on Nov 17, 2026Market cap $8.70MP/E –Yield –
Cellectar Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Cellectar Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $13.25M, down 24.4% year over year. For fiscal 2025 it was $11.50M, down 56.0% from the year before. Over ten years it grew 8.3% a year on average. The highest annual figure on record is $27.27M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.50M | -56.0% |
| FY2024 | Dec 31, 2024 | $26.14M | -4.1% |
| FY2023 | Dec 31, 2023 | $27.27M | +49.3% |
| FY2022 | Dec 31, 2022 | $18.27M | +3.9% |
| FY2021 | Dec 31, 2021 | $17.59M | +73.4% |
| FY2020 | Dec 31, 2020 | $10.14M | +12.7% |
| FY2019 | Dec 31, 2019 | $9.00M | +31.6% |
| FY2018 | Dec 31, 2018 | $6.84M | -27.8% |
| FY2017 | Dec 31, 2017 | $9.47M | +99.3% |
| FY2016 | Dec 31, 2016 | $4.75M | -7.9% |
| FY2015 | Dec 31, 2015 | $5.16M | -13.5% |
| FY2014 | Dec 31, 2014 | $5.96M | -13.1% |
| FY2013 | Dec 31, 2013 | $6.86M | +33.9% |
| FY2012 | Dec 31, 2012 | $5.12M | +42.3% |
| FY2011 | Dec 31, 2011 | $3.60M | +20.6% |
| FY2010 | Dec 31, 2010 | $2.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.56M | +90.7% |
| Q1 FY2026 | Mar 31, 2026 | $3.01M | -12.3% |
| Q4 FY2025 | Dec 31, 2025 | $3.16M | -49.1% |
| Q3 FY2025 | Sep 30, 2025 | $2.52M | -54.1% |
| Q2 FY2025 | Jun 30, 2025 | $2.39M | -67.5% |
| Q1 FY2025 | Mar 31, 2025 | $3.43M | -51.6% |
| Q4 FY2024 | Dec 31, 2024 | $6.21M | -19.8% |
| Q3 FY2024 | Sep 30, 2024 | $5.49M | -21.9% |
| Q2 FY2024 | Jun 30, 2024 | $7.35M | +19.7% |
| Q1 FY2024 | Mar 31, 2024 | $7.09M | +11.5% |
| Q4 FY2023 | Dec 31, 2023 | $7.74M | +71.9% |
| Q3 FY2023 | Sep 30, 2023 | $7.03M | +35.0% |
| Q2 FY2023 | Jun 30, 2023 | $6.14M | +48.0% |
| Q1 FY2023 | Mar 31, 2023 | $6.36M | +71.7% |
| Q4 FY2022 | Dec 31, 2022 | $4.50M | +2.5% |
| Q3 FY2022 | Sep 30, 2022 | $5.21M | +32.3% |
| Q2 FY2022 | Jun 30, 2022 | $4.14M | -10.4% |
| Q1 FY2022 | Mar 31, 2022 | $3.70M | -20.1% |
| Q4 FY2021 | Dec 31, 2021 | $4.39M | +84.8% |
| Q3 FY2021 | Sep 30, 2021 | $3.94M | +46.7% |
| Q2 FY2021 | Jun 30, 2021 | $4.63M | +87.7% |
| Q1 FY2021 | Mar 31, 2021 | $4.63M | +77.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.38M | +9.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.68M | -0.7% |
| Q2 FY2020 | Jun 30, 2020 | $2.47M | +36.2% |
| Q1 FY2020 | Mar 31, 2020 | $2.62M | +13.3% |
| Q4 FY2019 | Dec 31, 2019 | $2.17M | +109.7% |
| Q3 FY2019 | Sep 30, 2019 | $2.70M | +35.5% |
| Q2 FY2019 | Jun 30, 2019 | $1.81M | +5.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.31M | +8.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.04M | -66.6% |
| Q3 FY2018 | Sep 30, 2018 | $2.00M | -14.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.72M | -20.8% |
| Q1 FY2018 | Mar 31, 2018 | $2.12M | +14.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.10M | +115.2% |
| Q3 FY2017 | Sep 30, 2017 | $2.33M | +78.7% |
| Q2 FY2017 | Jun 30, 2017 | $2.18M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.86M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.44M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.31M | – |
See a number that looks wrong?